03/06/2018 Number of shares and voting rights of ADOCIA as of February 28, 2018 Icon check
02/17/2018 BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
02/14/2018 BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
02/12/2018 Number of shares and voting rights of ADOCIA as of January 31, 2018 Icon check
02/12/2018 Adocia: additional resources allocated to the liquidity agreement Icon check
02/09/2018 Adocia to Present at the 2018 BIO CEO & Investor Conference in New York Icon check
02/06/2018 Adocia Files Additional Arbitration Claims Against Eli Lilly & Company Icon check
01/25/2018 Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes Icon check
01/10/2018 Number of shares and voting rights of ADOCIA as of December 31, 2017 Icon check
01/08/2018 Adocia announces its financial calendar for 2018 Icon check
01/04/2018 Adocia announces expanded use of BioChaperone® beyond diabetes Icon check
12/07/2017 Number of shares and voting rights of ADOCIA as of November 30, 2017 Icon check
12/06/2017 Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes Icon check
11/20/2017 Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study Icon check
11/20/2017 “Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Excursions vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 1 Diabetes (T1DM)” (Poster 964) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
11/08/2017 Number of shares and voting rights of ADOCIA as of October 31, 2017 Icon check
10/20/2017 “Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Control vs. Insulin Lispro (LIS) in a14-Day Treatment Study in Subjects with Type 2 Diabetes (T2DM)” (Poster 994) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
10/12/2017 Number of shares and voting rights of ADOCIA as of September 30, 2017 Icon check
09/20/2017 “Proportional Dose-Exposure Relationship of Ultra-rapid BioChaperone® Lispro (BCLIS) in Healthy Japanese Subjects” (Poster 996), presented by Dr. Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
09/18/2017 Number of shares and voting rights of ADOCIA as of August 31, 2017 Icon check
09/05/2017 Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes Icon check
07/26/2017 Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer Icon check
07/19/2017 Adocia presents first half 2017 financial results Icon check
07/11/2017 Number of shares and voting rights of ADOCIA as of June 30, 2017 Icon check
06/14/2017 Adocia announces financial results for the third quarter 2017
06/09/2017 Number of shares and voting rights of ADOCIA as of May 31, 2017 Icon check
06/09/2017 “Preclinical Efficacy of a Stable Aqueous Formulation of Human Glucagon with BioChaperone® Technology (BC GLU)” (Poster 1150), presented by Dr Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
06/09/2017 “Profil pharmacodynamique de BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, chez des sujets diabétiques de type 2” (Abstract CAD-19), presented by Dr. Martin Gaudier, 2017, Société Francophone du Diabète (France)
06/09/2017 “L’insuline ultra-rapide BioChaperone® Lispro améliore le contrôle glycémique postprandial par rapport à Humalog® chez des sujets diabétiques de type 1” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2017, Société Francophone du Diabète (France)
06/09/2017 “BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, présente un contrôle glycémique amélioré par rapport à un premix d’insuline.” (Abstract CAD-19), presented by Dr. Claire Megret, 2017, Société Francophone du Diabète (France)
06/07/2017 Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes Icon check
06/06/2017 Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes Icon check
06/01/2017 Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump Icon check
06/01/2017 Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon Icon check
05/30/2017 Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions Icon check
05/30/2017 Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York Icon check
05/19/2017 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris Icon check
05/15/2017 Number of shares and voting rights of ADOCIA as of April 30, 2017 Icon check
04/18/2017 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 Icon check
04/18/2017 Adocia announces first quarter 2017 financial results Icon check
04/13/2017 Number of shares and voting rights of Adocia as of March 31, 2017 Icon check
03/13/2017 Number of shares and voting rights of ADOCIA as of February 28, 2017 Icon check
03/07/2017 ADOCIA announced its financial results for 2016 and its perspectives for 2017 Icon check
02/14/2017 Adocia announces its revenue and cash position for 2016 Icon check
02/13/2017 Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference Icon check
01/27/2017 Adocia to hold conference call on Monday January 30, 2017 Icon check
01/27/2017 Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro Icon check
01/25/2017 Adocia to hold conference call providing an update on its programs Icon check
01/19/2017 Adocia announces the transformation of its business model to increase the value of its projects Icon check
01/06/2017 Half year report on Adocia’s liquidity agreement with Kepler Chevreux
01/05/2017 Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes Icon check
01/04/2017 Adocia announces its financial calendar for 2017 Icon check
12/16/2016 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro Icon check
11/10/2016 Adocia to Participate in Upcoming Investor Conferences Icon check
11/07/2016 Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes Icon check
10/27/2016 Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Icon check
10/12/2016 Adocia announces third quarter 2016 financial results Icon check
09/22/2016 Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region Icon check
09/20/2016 Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes Icon check
09/19/2016 Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET) Icon check
Join our mailing list. Subscribe